{"id":"tp-55901","type":"article-newspaper","title":"Altimmune Reports $480 Million in Cash as Third-Quarter Loss Widens","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/55901","datePublished":"2026-11-12T21:06:06.000Z","dateModified":"2026-11-12T21:06:06.000Z","language":"en","abstract":"The company expects 52-week results from its Phase 3 PERFORMA trial in 2029 and RESTORE data in the second half of 2027.","section":"Business","references":[]}